Abstract
Diabetes mellitus is a major risk factor for cardiovascular disease. However, the excess risk of death may vary substantially in subgroups of patients with type 2 diabetes, being highest in those younger than 55 years of age. A HbA1c value of 7.0 % or less is recommended for most patients with type 2 diabetes to reduce the incidence of microvascular disease, although individualized approaches that balance the benefits of glycemic control against the harms of hypoglycemia are encouraged. The selection of antidiabetic medications is of paramount importance, as the drug should not aggravate, and ideally even improve cardiovascular risk factors, with the hope to reduce cardiovascular morbidity and mortality. Patients with diabetes mellitus between 40 and 75 years of age with LDL-C between 70 and 189 mg/dL should be treated with a moderate-intensity statin. Implicit in this recommendation is the aim to reduce further LDL-C level in diabetes, in order to improve the cardiovascular outlook. The new PCSK9 inhibitors (evolocumab and arilocumab) are very promising, but, at present, their cost-effectiveness ratios exceed commonly accepted thresholds. For many people with diabetes mellitus and hypertension blood pressure should be <140/90 mmHg, although lower systolic targets (e.g., <130 mmHg) may be appropriate for certain individuals. With the likely exception of LDL-C, it is difficult to define a universal HbA1c and blood pressure target for all patients with type 2 diabetes mellitus. Ultimately, in the face of uncertainty in medicine, the final decision regarding a specific patient is best left to the clinician.
Similar content being viewed by others
References
IDF Diabetes Atlas, Seventh Edition www.diabetesatlas.org. Accessed 1 April 2016
E.W. Gregg, Y. Li, J. Wang, N.R. Burrows, M.K. Ali, D. Rolka, D.E. Williams, L. Geiss, Changes in diabetes-related complications in the United States, 1990–2010. N. Engl. J. Med. 370, 1514–1523 (2014)
J. Ma, E.M. Ward, R.L. Siegel, A. Jemal, Temporal trends in mortality in the United States, 1969–2013. JAMA 314, 1731–1739 (2015)
E.W. Gregg, X. Zhuo, Y.J. Cheng, A.L. AlbrighL, K.M. Narayan, T.J. Thompson, Trends in lifetime risk and years of life lost due to diabetes in the USA, 1985–2011: a modelling study. Lancet Diabetes Endocrinol 2, 867–874 (2014)
M.K. Ali, K.M. Bullard, J.B. Saaddine, C.C. Cowie, G. Imperatore, E.W. Gregg, Achievement of goals in U.S. diabetes care, 1999–2010. N. Engl. J. Med. 368, 1613–1624 (2013)
L.S. Phillips, W.T. Branch, C.B. Cook, J.P. Doyle, I.M. El-Kebbi, D.L. Gallina, C.D. Miller, D.C. Ziemer, C.S. Barnes, Clinical inertia. Ann. Intern. Med. 135, 825–834 (2001)
D. Giugliano, K. Esposito, Clinical inertia as a clinical safeguard. JAMA 305, 1591–1592 (2011)
American Diabetes Association. 5, Glycemic target. Diabetes Care 39, S39–S46 (2016)
A.S. Go, D. Mozaffarian, V.L. Roger, E.J. Benjamin, J.D. Berry, W.B. Borden, D.M. Bravata, S. Dai, E.S. Ford, C.S. Fox, S. Franco, H.J. Fullerton, C. Gillespi, S.M. Hailpern, J.A. Heit, V.J. Howard, M.D. Huffman, B.M. Kissela, S.J. Kittner, D.T. Lackland, J.H. Lichtman, L.D. Lisabeth, D. Magid, G.M. Marcus, A. Marelli, D.B. Matchar, D.K. McGuire, E.R. Mohler, C.S. Moy, M.E. Mussolino, G. Nichol, N.P. Paynter, P.J. Schreiner, P.D. Sorlie, J. Stein, T.N. Turan, S.S. Virani, N.D. Wong, D. Woo, M.B. Turner, American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Executive summary: heart disease and stroke statistics–2013 update: a report from the American Heart Association. Circulation 127, 143–152 (2013)
The Emerging Risk Factors Collaboration, Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 375, 2215–2222 (2010)
M. Tancredi, A. Rosengren, A.M. Svensson, M. Kosiborod, A. Pivodic, S. Gudbjörnsdottir, H. Wedel, M. Clements, S. Dahlqvist, M. Lind, Excess mortality among persons with type 2 diabetes. New Engl J Med 373, 1720–1732 (2015)
UK Prospective Diabetes Study (UKPDS) Group, Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33. Lancet 352, 837–853 (1998)
V.M. Montori, M. Fernández-Balsells, Glycemic control in type 2 diabetes: time for an evidence-based about-face? Ann. Intern. Med. 150, 803–808 (2009)
B. Hemmingsen, S.S. Lund, C. Gluud, A. Vaag, T.P. Almdal, C. Hemmingsen, J. Wetterslev, Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus. Cochrane Database Syst. Rev. 11, 8143 (2013)
R.R. Holman, S.K. Paul, M.A. Bethel, D.R. Matthews, H.A. Neil, 10-year follow-up of intensive glucose control in type 2 diabetes. N. Engl. J. Med. 359, 1577–1589 (2008)
R.A. Hayward, P.D. Reaven, W.L. Wiitala, G.D. Bahn, D.J. Reda, L. Ge, M. McCarren, W.C. Duckworth, N.V. Emanuele, V.A.D.T. Investigators, Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 372, 2197–2206 (2015)
R.G. McCoy, H.K. Van Houten, J.Y. Ziegenfuss, N.D. Shah, R.A. Wermers, S.A. Smith, Increased mortality of patients with diabetes reporting severe hypoglycemia. Diabetes Care 35, 1897–1901 (2002)
J.A. Dormandy, B. Charbonnel, D.J. Eckland, E. Erdmann, M. Massi-Benedetti, I.K. Moules, A.M. Skene, M.H. Tan, P.J. Lefèbvre, G.D. Murray, E. Standl, R.G. Wilcox, L. Wilhelmsen, J. Betteridge, K. Birkeland, A. Golay, R.J. Heine, L. Korányi, M. Laakso, M. Mokán, A. Norkus, V. Pirags, T. Podar, A. Scheen, W. Scherbaum, G. Schernthaner, O. Schmitz, J. Skrha, U. Smith, J. Taton, PROactive investigators, Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366, 1279–1289 (2005)
ORIGIN Trial Investigators, Basal insulin and cardiovascular and other outcomes in dysglycemia. N. Engl. J. Med. 367, 319–328 (2012)
B.M. Scirica, D.L. Bhatt, E. Braunwald, P.G. Steg, J. Davidson, B. Hirshberg et al., SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N. Engl. J. Med. 369, 1317–1326 (2013)
W.B. White, C.P. Cannon, S.R. Heller, S.E. Nissen, R.M. Bergenstal, G.L. Bakris et al., EXAMINE Investigators. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N. Engl. J. Med. 369, 1327–1335 (2013)
G. Schernthaner, N. Sattar, Lessons from SAVOR and EXAMINE: some important answers, but many open questions. J Diab. Compl. 28, 430–433 (2014)
M.A. Pfeffer, B. Claggett, R. Diaz, K. Dickstein, H.C. Gerstein, L.V. Køber, The ELIXA Investigators et al., Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N. Engl. J. Med. 373, 2247–2257 (2015)
J.B. Green, M.A. Bethel, P.W. Armstrong, J.B. Buse, S.S. Engel, J. Garg, The TECOS Study Group et al., Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 373, 232–242 (2015)
B. Zinman, C. Wanner, J.M. Lachin, D. Fitchett, E. Bluhmki, S. Hantel, The EMPA-REG OUTCOME Investigators, Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N. Engl. J. Med. 373, 2117–2128 (2015)
L. Li, S. Li, K. Deng, J. Liu, P.O. Vandvik, P. Zhao et al., Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomized and observational studies. BMJ 352, i610 (2016)
C.P. Cannon, M.A. Blazing, R.P. Giugliano, A. McCagg, J.A. White, P. Theroux, The IMPROVE-IT Investigators et al., Ezetimibe added to statin therapy after acute coronary syndromes. N. Engl. J. Med. 372, 2387–2397 (2015)
R.D. Santos, G.F. Watts, Familial hypercholesterolaemia: PCSK9 inhibitors are coming. Lancet 385, 307–310 (2015)
E.P. Navarese, M. Kolodziejczak, V. Schulze, P.A. Gurbel, U. Tantry, Y. Lin et al., Effects of proprotein convertase subtilisin/kexin type 9 antibodies in adults with hypercholesterolemia. Ann. Intern. Med. 163, 40–51 (2015)
N. Sattar, D. Preiss, J.G. Robinson, C.S. Djedjos, M. Elliott, R. Somaratne, S.M. Wasserman, F.J. Raal, Lipid-lowering efficacy of the PCSK9 inhibitor evolocumab (AMG 145) in patients with type 2 diabetes: a meta-analysis of individual patient data. Lancet Diabetes Endocrinol 4(5), 403–410 (2016)
R.D. Santos, PCSK9 inhibition in type 2 diabetes: so far so good, but not there yet. Lancet Diabetes Endocrinol 4(5), 377 (2016)
UK Prospective Diabetes Study Group, Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 317, 703–713 (1998)
P.A. James, S. Oparil, B.L. Carter, W.C. Cushman, C. Dennison-Himmelfarb, J. Handler et al., 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 311, 507–520 (2014)
C.A. Emdin, K. Rahimi, B. Neal, T. Callender, V. Perkovic, A. Patel, Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis. JAMA 313, 603–615 (2015)
M. Brunström, B. Carlberg, Effect of antihypertensive treatment at different blood pressure levels in patients with diabetes mellitus: systematic review and meta-analyses. BMJ 352, i717 (2016)
S.E. Inzucchi, R.M. Bergenstral, J.B. Buse et al., Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 38, 140–149 (2015)
J.A. Tice, D.S. Kazi, S.D. Pearson, Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors for treatment of high cholesterol levels: effectiveness and value. JAMA Intern. Med. 176, 107–108 (2016)
X. Xie, E. Atkins, J. Lv et al., Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. Lancet 387, 435–443 (2016)
K. Esposito, M.I. Maiorino, G. Bellastella, D. Giugliano, New guidelines for metabolic targets in diabetes: clinician’s opinion does matter. Endocrine 46, 431–434 (2014)
P. Gaede, P.H. Lund-Andersen, H.H. Parving, O. Pedersen, Effect of a multifactorial intervention on mortality in type 2 diabetes. N. Engl. J. Med. 358, 580–591 (2008)
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
D.G. and K.E. received speaker fees from Lilly, SANOFI, and NOVARTIS.
Rights and permissions
About this article
Cite this article
Giugliano, D., Maiorino, M.I., Bellastella, G. et al. Glucose, cholesterol, and blood pressure: is lower always better for type 2 diabetes?. Endocrine 54, 32–37 (2016). https://doi.org/10.1007/s12020-016-0981-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12020-016-0981-y